NYSEAMERICAN:BTX - BioTime Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.9998 -0.07 (-6.54 %) (As of 01/20/2019 12:11 PM ET)Previous Close$0.9998Today's Range$0.9770 - $1.0952-Week Range$0.66 - $3.16Volume808,819 shsAverage Volume370,831 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California. Receive BTX News and Ratings via Email Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryBiotechnology SectorMedical Current SymbolNYSEAMERICAN:BTX Previous SymbolNYSEMKT:BTX CUSIP09066L10 Webwww.biotimeinc.com Phone+1-510-5213390Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees92 Outstanding Shares126,964,000Market Cap$0.00 OptionableOptionable BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions What is BioTime's stock symbol? BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX." How were BioTime's earnings last quarter? BioTime, Inc. (NYSEAMERICAN:BTX) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The biotechnology company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $0.75 million. View BioTime's Earnings History. When is BioTime's next earnings date? BioTime is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for BioTime. What price target have analysts set for BTX? 3 Wall Street analysts have issued 12-month price objectives for BioTime's stock. Their predictions range from $3.50 to $8.00. On average, they anticipate BioTime's share price to reach $5.00 in the next year. This suggests a possible upside of 400.1% from the stock's current price. View Analyst Price Targets for BioTime. What is the consensus analysts' recommendation for BioTime? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime. Has BioTime been receiving favorable news coverage? News stories about BTX stock have been trending extremely positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioTime earned a coverage optimism score of 4.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. Are investors shorting BioTime? BioTime saw a decrease in short interest in December. As of December 31st, there was short interest totalling 11,732,847 shares, a decrease of 18.1% from the December 14th total of 14,320,748 shares. Based on an average daily volume of 1,152,378 shares, the days-to-cover ratio is currently 10.2 days. Currently, 9.3% of the shares of the stock are short sold. View BioTime's Current Options Chain. Who are some of BioTime's key competitors? Some companies that are related to BioTime include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB). Who are BioTime's key executives? BioTime's management team includes the folowing people: Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)Mr. Brian M. Culley, CEO , Pres & Director (Age 48)Mr. David Nakasone, Director of Investor Relations Who are BioTime's major shareholders? BioTime's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.03%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime. Which institutional investors are buying BioTime stock? BTX stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime. How do I buy shares of BioTime? Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTime's stock price today? One share of BTX stock can currently be purchased for approximately $0.9998. What is BioTime's official website? The official website for BioTime is http://www.biotimeinc.com/. How can I contact BioTime? BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390. MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 166 (Vote Underperform)Total Votes: 330MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: What is the Federal Reserve?